Aharon Gal
Chief Strategy & Growth OfficerNovartis
PharmaceuticalsView Profile →Executive Vice President, Product & Portfolio Strategy · Novo Nordisk
Hong Chow leads product and portfolio strategy at Novo Nordisk, following international pharmaceutical leadership at Merck, Roche and Bayer.
Last reviewed: Nov 15, 2026
Hong Chow leads product and portfolio strategy at Novo Nordisk, following international pharmaceutical leadership at Merck, Roche and Bayer.
Chow began her career as a business analyst with Deloitte Consulting in London before entering the pharmaceutical industry in 1997. At Bayer Healthcare, she held leadership assignments spanning China, Asia-Pacific and Europe. She subsequently led Roche’s pharmaceutical business in China.
In October 2021, she joined Merck KGaA as head of China and International for Healthcare. That remit covered China and Japan, as well as Europe, Latin America, Asia-Pacific, the Middle East, Africa and Russia. She also held responsibility for cardiovascular, metabolism and endocrinology products and global business innovation.
Her later Merck responsibilities included global health and health equity. She served on the Healthcare Executive Committee before moving to Novo Nordisk in February 2026 as executive vice president for Product and Portfolio Strategy. The Novo portfolio brings together commercial strategy, global medical affairs and business development across therapy areas.
Chow has also served on Beiersdorf’s supervisory board since 2017. Her academic training was a dual programme in European business administration: she received qualifications from the Berlin School of Economics and Law and Anglia Ruskin University in 1996.